A closer look at NativeMUSE™ by Dux Bio and the science of leaving Wharton’s jelly alone

NativeMUSE™ is a Multilineage-differentiating Stress-Enduring (MUSE) cell product derived from umbilical cord Wharton’s jelly — and what sets it apart starts with what Dux Bio doesn’t do to the tissue. There is no cell culture, no ex vivo expansion, and no enzymatic digestion anywhere in the process. The MUSE cells in NativeMUSE™ are not isolated, multiplied in a bioreactor, and reintroduced weeks later as a manufactured cell line. They are present in the tissue as harvested, still situated in the matrix they occupied naturally.

That distinction matters more than it might first appear. Many MUSE and mesenchymal stem cell products on the market today rely on enzymatic digestion — typically collagenase — to break the tissue apart and release cells into suspension, often followed by weeks of culture expansion to reach a target cell count. Each of those steps moves the product further from the tissue’s original state and closer to a laboratory-engineered one. NativeMUSE™ skips both. The tissue is processed, not digested or expanded, which keeps the product close to what MUSE cells look like in their native environment: embedded in Wharton’s jelly, not floating free in a culture flask.

This is also the foundation of why NativeMUSE™ is positioned as a minimally manipulated tissue product. Without enzymatic digestion or expansion altering the tissue’s original structural characteristics, the umbilical cord’s own extracellular matrix (ECM) — the gel-like network of hyaluronic acid, collagen, and proteoglycans that Wharton’s jelly is built from — comes through the process largely intact, along with the resident MUSE cell population it was always meant to support.

The Case for Minimal Manipulation

Human cell and tissue products intended for clinical use in the United States generally fall into one of two regulatory pathways under the FDA’s framework for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Section 351 of the Public Health Service Act, which treats a product as a biologic drug requiring premarket approval, or Section 361, which applies to tissues that meet a narrower set of criteria — most notably that the tissue is minimally manipulated and intended for homologous use.

“Minimal manipulation” is not a marketing term. For structural tissue, FDA defines it as processing that does not alter the tissue’s original relevant biological characteristics relating to its utility for reconstruction, repair, or replacement. In practical terms, that means the processing method itself has to leave the tissue’s native structure intact — not just its cells, but the matrix those cells live in.

This is where many processing methods for birth tissue products run into trouble. Enzymatic digestion — using collagenase or similar enzymes to break down the ECM and release cells into a suspension — is efficient for isolating large numbers of cells. But it also does exactly what “minimal manipulation” is designed to prevent: it fundamentally alters the tissue’s structural characteristics by dissolving the matrix that gave the tissue its original biological function.

What “No Additives, No Enzymes” Actually Means

NativeMUSE™ is processed without enzymatic digestion and without added chemical agents to strip or dissociate the tissue. There is no collagenase step, no added growth factors, no synthetic scaffolding, and no combination with another article beyond what the framework permits for a Section 361 tissue. The Wharton’s jelly matrix is handled, not dismantled.

The practical consequence is that the resulting product isn’t a cell suspension stripped of its surroundings — it retains a meaningful proportion of its native extracellular matrix. The MUSE cells present in the tissue remain embedded in something resembling their original environment, rather than floating free in a digestion buffer.

Why the Matrix Matters, Not Just the Cells

It’s tempting to think of a stem cell product purely in terms of cell counts and viability percentages. But the ECM surrounding those cells inside the umbilical cord was never inert packaging — it performed active biomechanical work:

• Protection — the jelly cushions the umbilical vessels against compression and mechanical stress
• Cushioning — its viscoelastic, hydrated structure absorbs and distributes load
• Lubrication — hyaluronic acid within the matrix reduces friction between the cord’s internal structures
• Structural support — collagen and proteoglycan networks maintain the tissue’s shape and integrity under stress

A product that preserves significant ECM content is, in effect, carrying that same structural toolkit into the clinical setting. Rather than delivering an isolated population of cells with no supporting environment, minimally manipulated Wharton’s jelly-derived tissue arrives with a matrix that still performs recognizable mechanical and biological roles — the same functions it performed for nine months in utero, just relocated to a different application.

The Regulatory Logic, in Plain Terms

This is more than a philosophical preference for “natural” processing. It’s the regulatory logic underpinning the entire Section 361 framework. FDA’s minimal manipulation standard exists specifically to distinguish tissues that retain their original structural function from those that have been re-engineered into something biologically new. A product that keeps its native matrix intact has a more straightforward path to sitting inside that structural-tissue category — because it hasn’t been transformed into a different kind of product in the first place.

This is also why processing choices at the front end of manufacturing carry so much downstream weight. A product that starts with enzymatic digestion has already made a structural claim about itself — one that pulls it further from the criteria for minimal manipulation, regardless of how the resulting cells test in a lab. A product that starts by preserving the matrix keeps that structural framing available throughout its regulatory and clinical life.

Built to Match the Tissue’s Original Design

NativeMUSE™ reflects a processing philosophy at Dux Bio: don’t fight the tissue’s original design, work with it. The Wharton’s jelly matrix spent nine months doing a specific job. Preserving that matrix — rather than dissolving it in pursuit of a higher raw cell count — keeps that original functional design intact and available for its next application.

For providers evaluating birth tissue-derived products, the processing method is not a footnote. It is the determining factor in what actually ends up in the vial: an isolated population of cells with no supporting structure, or a tissue-based product that still carries the protective, cushioning, lubricating, and structurally supportive matrix nature built around it in the first place.

This content is intended for educational and informational purposes for healthcare providers and is not intended as a claim of FDA approval or clearance. NativeMUSE™ is regulated as a human cell and tissue product under 21 CFR Part 1271 and is not FDA-approved, cleared, or licensed.